“We are not great in the gastro [segment]… we have decided that we are supposed to work a lot in gastro because it has become semi-chronic, and our inclination is towards the chronic side, “Juneja said, adding thatgastro in Indian is one of the fasting Segments.
“Along with this, we are working on derma as well,” He said.
The Gastro Segment Grew 7.3% Year on Year in April, According to Pharma Intelligence Platform PHARMARCK.
Further, Mankind is developing a novel anti-obesity and diabetes drug in-House. The Drug Candidate, GRP119, is currently in Phase 2 Trials in Australia, and Juneja said that Results are expected in the next six to nine months.
In FY25, Mankind Signed A Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialise Its Novel Drug Vonoprazan, to Trat Gastroesophageal Reflux disease (GERD).
Juneja said that the company is evaluating all options to increase its presence in these therapy areas, including in-learning products from innovators or small experts.
“No Past Strategy Can Be Guaranteed for Future Success. So we need to apply our mind and try to brings some kind of differentiation in wheatver we do,” said june. “The point is that once we decide that our intention is that we are supposed to be good on the gastro side, we start searching for avenues, we start searching for people, we start search for pro.
The company will also continue to strengthen its health segment in the women’s health segment, which received a boost last last year through its acquisition of bharat serum and Vaccines (BSV).
With its foundation strengthened in fy25, mankind aims to grow 1.2 to 1.3 times the Indian Pharmaceutical Market. Juneja said this will be driven by its focus on its chronic domestic formulations portfolio.
Juneja said the focus is also on growing larger brands, from the current 50 Crore to 100 Crore brands for products to 500 Crore brands.
“This is the strategy we basically want to pursue in future, we have seen that once you create that kind of a brand, that’s a very big entry barrier,” he added.
BSV Acquisition
Mankind is on track with the integration of bsv, which it acqured for 13,768 Crore in October 2024. The integration will be funded through a mix of internal accruals and external debt.
Juneja said the company focused on removing the “extra flab” and brings in the right talent for the acqured entity in fy25. This year, he expects 18-20% growth from the bsv portfolio. The goal is to increase the reach and awareness of bsv’s niche super-expressiality products.
BSV is working on two biosimilars, the company’s investor presentation highlighted, although juneja declined to share more details on the bsv pipeline.
Vishal Manchanda, Senior Vice President of Institutional Equites at Systematix Group, ToldMintThat BSV’s Platform and SkillSet for Making Recombinant Drugs (Created by Inserting Ganes from One Species Into a Host Species) Can Be Leverned to make biosimilers.
Select Companies in India, Including Biocon, are skilled at the recombinant process. However, manchanda pointed out that mankind has the potential to scale this up meaningfully.
Innovation push
“If you’re a pharma company, naturally, you Gain Respect once you have great r & d,” Juneja said. “We Started Our Own R & D in Mankind 13-14 Years Back… Going forward, we’ll be putting a bit more money in the r & d side… our r & d expenses will increase believe
“We wish to become a bigger company… our dream is to become India’s number one company on the domestic side,” Juneja said, adding that “we need to have certain innovative products, and your working for”.
Mankind’s focus on innovation and specialty segments come as the Indian Pharmaceutical Market has become more crowded. Most segments alredy have estimated market leaders.
“… The promoters are realising that there is a challenge to growth. And they know they have been playing in is now kind of different to expert to expert to experts from where, meaningfully extra Think Mankind Promoters Being Extremely Committed to India Business, they are also also prepared on how to take this forward, “Manchanda said.
“What they are looking for a bigger avenue to build growth on,” He added, referring to mankind’s bsv accustion.
Internal corrections
Mankind Undertook Several Internal Correction Initiatives in the last year, Including Leadership Changes and Improving Synergies Between its Divisions, Juneja said.
“If you look at the history of mankind, in 30 years, we have become the fourth largest company,” juneja said, adding that for any company growing very fast, there comes a time when growth plateausus.
“But once you brings commanderial excellence, you brings people from outseide… a number of flws can come in front of you, and you have two two people: eite to remove that flaws gruly Your sales and profit and growth, or second, do it immediatily, “Juneja said.
“We belong to the second category, and we decide that by March 2025, We’ll Clean Up Mankind from Every Side,” He Added.